Trial Profile
A Phase Randomized Open Labelled Controlled Dose Escalation Study of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B-infected Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Oct 2012
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary) ; Interleukin-7 (Primary) ; Entecavir; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Adverse reactions
- Acronyms CONVERT
- Sponsors Revimmune SAS
- 17 Oct 2012 Planned end date changed from 1 Nov 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 17 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Dec 2009 New trial record